Ryzodeg Approved in Japan

Novo Nordisk announced that the Japanese Ministry of Health has approved Ryzodeg® (insulin degludec/insulin aspart) for the treatment of diabetes. Ryzodeg is a soluble formulation of Tresiba (insulin degludec), a once-daily new generation basal insulin analogue with an ultra-long duration of action, and NovoRapid® (insulin aspart which in the US is marketed under the brand name NovoLog®). Ryzodeg can be administered once or twice daily with the main meal(s). In global treat-to-target studies supporting the new drug application, where Ryzodeg was compared to NovoMix®, Ryzodeg demonstrated a significantly lower risk of nocturnal hypoglycemia while successfully achieving equivalent reductions in HbA1c. Ryzodeg is awaiting approval from the FDA.